TGM4: an immunogenic prostate-restricted antigen

BACKGROUND: Prostate cancer is the second leading cause of cancer-related death in men in the USA; death occurs when patients progress to metastatic castration-resistant prostate cancer (CRPC). Although immunotherapy with the Food and Drug Administration‐approved vaccine sipuleucel‐T, which targets...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopez-Bujanda, Zoila A, Obradovic, Aleksandar, Nirschl, Thomas R, Crowley, Laura, Macedo, Rodney, Papachristodoulou, Alexandros, O’Donnell, Timothy, Laserson, Uri, Zarif, Jelani C, Reshef, Ran, Yuan, Tiezheng, Soni, Mithil K, Antonarakis, Emmanuel S, Haffner, Michael C, Larman, H Benjamin, Shen, Michael M, Muranski, Pawel, Drake, Charles G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246381/
https://www.ncbi.nlm.nih.gov/pubmed/34193566
http://dx.doi.org/10.1136/jitc-2020-001649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246381/
https://www.ncbi.nlm.nih.gov/pubmed/34193566
http://dx.doi.org/10.1136/jitc-2020-001649

Ejemplares similares